Rapport Therapeutics, Inc. (RAPP) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$43.00

From 52W high−22.95%

Volume973073.00

Market cap$1.94B

P/E (TTM)—

P/S (TTM)97.0x

Div yield—

Key dataSep 18, 2026

Open

$43.00

From 52W high

−22.95%

Volume

973073.00

Market cap

$1.94B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−10.2x

P/E (TTM)

—

RSI (14)

32.6

MomentumView details →

1D Return

−3.58%

YTD Return

+33.65%

SummaryUpdated Jun 1, 2026

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Boston, Massachusetts. The company was originally incorporated as Precision Neuroscience NewCo, Inc. before changing its name in October 2022. Rapport focuses on discovering and developing small molecule medicines to treat central nervous system disorders, representing a relatively young entrant in the competitive biotechnology sector with a specialized focus on neurological conditions.

Ask drillr about Rapport Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−10.2x

EV/Sales

75.7x

P/S (TTM)

97.0x

P/B (TTM)

4.6x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−685.80%

EBITDA Margin

−740.69%

ROE (TTM)

−32.43%

ROA (TTM)

−29.88%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

—

EPS YoY

−87.48%

FCF YoY

−26.42%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+24.34%

EBITDA YoY

−46.98%

MomentumView details →

1D Return

−3.58%

YTD Return

+33.65%

1Y Return

+53.83%

RSI (14)

32.6

vs 50D SMA

−9.45%

vs 200D SMA

+14.25%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

15.72x

Quick Ratio

15.72x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.19

EPS Surprise

−6.25%

Beats (12Q)

6/12

Next Q EPS Est

−$1.20

Avg Surprise (4Q)

3.99%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

20.00M

Net Income (TTM)

−137.16M

Op. CF (TTM)

−96.68M

Next earningsNov 5, 2026 →

Latest newsMore news →

Rapport Therapeutics reported a net loss of $56.6 million for Q2 2026, compared to a net loss of $26.7 million in Q2 2025, with diluted EPS of -$1.19.47d ago

Similar companies

GH Research PLCGHRS Mesoblast LimitedMESO Agios Pharmaceuticals, Inc.AGIO AIM Vaccine Co., Ltd.06660.HK *ST海利603718.SH Fortrea Holdings Inc.FTRE Find similar companies →

Latest newsMore news →

Rapport Therapeutics reported a net loss of $56.6 million for Q2 2026, compared to a net loss of $26.7 million in Q2 2025, with diluted EPS of -$1.19.47d ago